After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.

The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.

The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.

The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

The new consortium, dubbed Thera4Care, launched with €25.3 million in EU government funding and 29 academic and industry partners.

In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.

Astellas will make a $20 million equity investment in AviadoBio for the option to exclusively develop and commercialize AVB-1010.

Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who ...

The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.

The decision reaffirming the FDA's oversight authority over cell and gene therapy products was praised by the International ...